Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26705198 | 0.85 | NCF1 (0.41) | ACHE | |
| SCHEMBL27097463 | 0.81 | NPC1 (0.44) | CYP1A2ACHEHTR4NPC1SIGMAR1 | |
| SCHEMBL27097465 | 0.81 | ACHE (0.62) | ACHECHRM5ADRA2CALDH1A1 | |
| SCHEMBL13401 | 0.80 | CYP1A2 (0.42) | CYP1A2NPC1CHRM5ADRA2CALDH1A1 | |
| SCHEMBL11850078 | 0.80 | CYP1A2 (0.48) | CYP1A2ACHENPC1SIGMAR1CHRM5 | |
| SCHEMBL17828184 | 0.79 | ACHE (0.64) | CYP1A2ACHESIGMAR1CHRM5ADRA2C | |
| SCHEMBL24146230 | 0.78 | CYP1A2 (0.44) | CYP1A2ACHENPC1SIGMAR1CHRM5 | |
| SCHEMBL25567744 | 0.78 | CYP1A2 (0.44) | CYP1A2ACHENPC1SIGMAR1CHRM5 | |
| SCHEMBL12945 | 0.78 | CHRM5 (0.58) | CYP1A2SIGMAR1CHRM5ADRA2CCHRM3 | |
| SCHEMBL30340999 | 0.78 | CHRM5 (0.58) | CYP1A2SIGMAR1CHRM5ADRA2CCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CYP1A2 4777/4885ACHE 3025/4885HTR4 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.